Zoetis Launches Portela for Osteoarthritis Pain Relief in Cats with Significant Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Should l Buy ZTS?
Source: Newsfilter
- New Drug Approval: Zoetis announced that Portela™ (relfovetmab injection) has been approved by Health Canada, designed to provide three months of osteoarthritis pain relief in cats with a single injection, marking a significant advancement in feline pain management.
- Successful Clinical Trials: In a nine-month field trial in Europe, Portela demonstrated significant efficacy in alleviating pain and was well tolerated even in cats with kidney disease, which is expected to enhance awareness and treatment of osteoarthritis among cat owners.
- Broad Market Potential: Zoetis anticipates commercial availability of Portela in 2026, aiming to address the unmet medical needs of up to 40% of cats, thereby enhancing the company's competitive position in the animal health market.
- Commitment to Innovation: Portela joins Zoetis's portfolio of osteoarthritis pain products, showcasing the company's ongoing commitment to innovation in animal medicine, aimed at improving the quality of life for pets through new therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZTS
Wall Street analysts forecast ZTS stock price to rise
12 Analyst Rating
7 Buy
5 Hold
0 Sell
Moderate Buy
Current: 117.290
Low
130.00
Averages
154.20
High
200.00
Current: 117.290
Low
130.00
Averages
154.20
High
200.00
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
2026 S&P 500 Market Outlook
- Historical Indicator Confidence: Research from LPL Financial shows that since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for long-term investors despite a 7% drop at the start of 2026.
- Market Resilience Analysis: Data from Ryan Detrick indicates that despite numerous geopolitical shock events since 1940, the median market return of the S&P 500 12 months later was 7.4%, suggesting that the market has a strong recovery capability over the long term, encouraging investors to continue regular contributions.
- Investment Sentiment Factors: Investor optimism during uncertain times may drive market rebounds, and while short-term corrections of 10% and bear markets every three and a half years are common, long-term investing is still viewed as an effective strategy for beating inflation and building wealth.
- Recommended Investment Strategy: Despite current market turbulence, analysts suggest focusing on reasonably valued potential stocks, with the Motley Fool's analyst team identifying 10 best stocks expected to yield significant returns in the coming years, further emphasizing the importance of adhering to long-term investment principles in uncertain environments.
See More
2026 Stock Market Outlook and Investor Confidence
- January Indicator Confidence: According to LPL Financial, since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for investors in 2026, especially with a 1.5% rise this January.
- Market Resilience Analysis: Despite geopolitical events, Ryan Detrick from Carson Group found that since 1940, the median market return of the S&P 500 twelve months after such events is 7.4%, indicating that the market rises 63% of the time, allowing investors to continue regular investments.
- Long-term Investment Philosophy: Detrick emphasizes that while the market may experience short-term volatility, the long-term trend is upward, aligning with Motley Fool co-founder David Gardner's view that long-term investing is one of the best ways to create wealth and combat inflation.
- Stocks to Watch: Amid current market turmoil, stocks like Amazon, MercadoLibre, Sprouts Farmers Market, and Zoetis are attracting investor attention, trading at reasonable valuations of 15x, 31x, 14x, and 17x earnings respectively, indicating promising investment opportunities.
See More
Stablecoins Evolving into Macro-Relevant Financial Layer
- Market Size Growth: The total supply of stablecoins has surpassed $300 billion, a significant increase from approximately $30 billion in 2020, indicating their rising importance in the global financial system and potential to reshape payments, remittances, and asset tokenization.
- Link to U.S. Treasuries: Stablecoin issuers typically invest in low-risk liquid assets like U.S. Treasury bills, making them important marginal buyers of short-dated government debt, thereby establishing a new connection between global payment demand and U.S. Treasury markets.
- Geographic Expansion Trend: The adoption of stablecoins is expanding in emerging economies facing inflation, currency depreciation, or capital controls, where digital dollar tokens serve as a store of value and provide access to dollar-based financial services outside the traditional banking system.
- Competitive Pressure on Banks: The growth of stablecoins may draw funds away from traditional bank deposits, particularly non-interest-bearing transaction accounts, forcing banks to compete more aggressively for funding, which could impact their operational models and profitability.
See More
Zoetis CEO to Participate in Healthcare Forum
- Executive Participation: Zoetis CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, at 10:30 AM ET, showcasing the company's leadership in animal health.
- Live Webcast Available: The audio webcast of the event will be accessible via the Zoetis investor website, ensuring that global stakeholders can stay updated on the company's latest developments, enhancing transparency.
- Company Background: As the world's leading animal health company with nearly 75 years of history, Zoetis is dedicated to advancing the future of animal care through innovation, serving veterinarians, livestock producers, and pet owners in over 100 countries.
- Innovation-Driven Growth: The company leverages deep scientific expertise and data-driven R&D to continuously deliver medicines, vaccines, and digital solutions, aiming to elevate animal health standards and meet customer needs.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
2026 S&P 500 Market Outlook
- Historical Indicator Confidence: Research from LPL Financial shows that since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for long-term investors despite a 7% drop at the start of 2026.
- Market Resilience Analysis: Data from Ryan Detrick indicates that despite numerous geopolitical shock events since 1940, the median market return of the S&P 500 12 months later was 7.4%, suggesting that the market has a strong recovery capability over the long term, encouraging investors to continue regular contributions.
- Investment Sentiment Factors: Investor optimism during uncertain times may drive market rebounds, and while short-term corrections of 10% and bear markets every three and a half years are common, long-term investing is still viewed as an effective strategy for beating inflation and building wealth.
- Recommended Investment Strategy: Despite current market turbulence, analysts suggest focusing on reasonably valued potential stocks, with the Motley Fool's analyst team identifying 10 best stocks expected to yield significant returns in the coming years, further emphasizing the importance of adhering to long-term investment principles in uncertain environments.
See More
2026 Stock Market Outlook and Investor Confidence
- January Indicator Confidence: According to LPL Financial, since 1950, when the S&P 500 posts positive returns in January, it achieves positive returns for the full year 89% of the time, with an average gain of 16.7%, providing confidence for investors in 2026, especially with a 1.5% rise this January.
- Market Resilience Analysis: Despite geopolitical events, Ryan Detrick from Carson Group found that since 1940, the median market return of the S&P 500 twelve months after such events is 7.4%, indicating that the market rises 63% of the time, allowing investors to continue regular investments.
- Long-term Investment Philosophy: Detrick emphasizes that while the market may experience short-term volatility, the long-term trend is upward, aligning with Motley Fool co-founder David Gardner's view that long-term investing is one of the best ways to create wealth and combat inflation.
- Stocks to Watch: Amid current market turmoil, stocks like Amazon, MercadoLibre, Sprouts Farmers Market, and Zoetis are attracting investor attention, trading at reasonable valuations of 15x, 31x, 14x, and 17x earnings respectively, indicating promising investment opportunities.
See More
Stablecoins Evolving into Macro-Relevant Financial Layer
- Market Size Growth: The total supply of stablecoins has surpassed $300 billion, a significant increase from approximately $30 billion in 2020, indicating their rising importance in the global financial system and potential to reshape payments, remittances, and asset tokenization.
- Link to U.S. Treasuries: Stablecoin issuers typically invest in low-risk liquid assets like U.S. Treasury bills, making them important marginal buyers of short-dated government debt, thereby establishing a new connection between global payment demand and U.S. Treasury markets.
- Geographic Expansion Trend: The adoption of stablecoins is expanding in emerging economies facing inflation, currency depreciation, or capital controls, where digital dollar tokens serve as a store of value and provide access to dollar-based financial services outside the traditional banking system.
- Competitive Pressure on Banks: The growth of stablecoins may draw funds away from traditional bank deposits, particularly non-interest-bearing transaction accounts, forcing banks to compete more aggressively for funding, which could impact their operational models and profitability.
See More
Zoetis CEO to Participate in Healthcare Forum
- Executive Participation: Zoetis CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, at 10:30 AM ET, showcasing the company's leadership in animal health.
- Live Webcast Available: The audio webcast of the event will be accessible via the Zoetis investor website, ensuring that global stakeholders can stay updated on the company's latest developments, enhancing transparency.
- Company Background: As the world's leading animal health company with nearly 75 years of history, Zoetis is dedicated to advancing the future of animal care through innovation, serving veterinarians, livestock producers, and pet owners in over 100 countries.
- Innovation-Driven Growth: The company leverages deep scientific expertise and data-driven R&D to continuously deliver medicines, vaccines, and digital solutions, aiming to elevate animal health standards and meet customer needs.
See More
Strong Dividends and Innovation Drive Healthcare Stocks
- Strong Dividend Record: Johnson & Johnson has raised its dividend for 50 consecutive years and expects to surpass $100 billion in sales this year for the first time, showcasing its stability and appeal to income-seeking investors amid economic fluctuations.
- Innovative Product Pipeline: Johnson & Johnson is awaiting approval for its robotic-assisted surgery system, Ottava, which could serve as a significant growth driver, while the company is also conducting dozens of clinical trials to expand its pharmaceutical portfolio.
- Leader in Animal Health: Zoetis has increased its dividend by 458% over the past decade, and despite facing safety concerns and competitive pressures, the launch of new products like Lenivia and Portela will support its continued growth in the pet healthcare market.
- Pet Ownership Trend Among Youth: Zoetis is capitalizing on the trend of younger generations increasingly choosing to own pets over having children by introducing innovative medications like Apoquel, which is expected to further solidify its market position and drive future revenue growth.
See More
Top Dividend Stocks to Buy: Johnson & Johnson and Zoetis
- Johnson & Johnson's Stability: Johnson & Johnson expects its 2023 sales to exceed $100 billion for the first time, demonstrating strong revenue and earnings growth despite challenges like patent expirations and drug price negotiations, highlighting its resilience and long-term investment value in the healthcare sector.
- Innovation-Driven Growth: The company is awaiting approval for its robotic-assisted surgery system, Ottava, which could be a significant growth driver, while its pharmaceutical pipeline includes dozens of ongoing clinical trials that enhance its competitive position in the market.
- Zoetis' Market Leadership: As a leader in animal health, Zoetis faces challenges from safety concerns, but the approval of new products Lenivia and Portela presents new growth opportunities, especially given their more favorable dosing frequency compared to predecessors.
- Dividend Growth Potential: Zoetis has increased its dividend by an impressive 458% over the past decade, reflecting its strong cash flow and profitability, making it an attractive option for income-seeking investors, particularly as younger generations increasingly choose pet ownership over having children.
See More
